Literature DB >> 11083492

The treatment of established intracranial tumors by in situ retroviral IFN-gamma transfer.

M Saleh1, N K Jonas, A Wiegmans, S S Stylli.   

Abstract

Current treatments for malignant gliomas are still largely ineffective in significantly improving prognosis. We have investigated the efficacy of treating established rat C6 glioma by in situ retroviral delivery of IFN-gamma cDNA. Ecotropic retrovirus packaging cells were transfected with a retroviral vector containing the mouse IFN-gamma gene. The IFN-gamma packaging cells were stereotactically implanted into established intracranial C6 glioma in immunocompetent Wistar rats, resulting in the eradication of these tumors. All IFN-gamma-treated rats survived to 92 days after C6 implantation (an arbitrary end point) compared with 14 days for controls. Analysis of these treated brains showed that the established C6 tumors had been completely eradicated by this time-point with brain morphology appearing normal. The IFN-gamma-mediated tumoricidal activity resulted from an apparent interplay of B and T cell components of the immune system, as well as the inhibition of tumor angiogenesis. This therapeutic strategy may provide an effective method of eradicating established intracranial tumors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11083492     DOI: 10.1038/sj.gt.3301273

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  10 in total

Review 1.  C6 cell line: the gold standard in glioma research.

Authors:  D Giakoumettis; A Kritis; N Foroglou
Journal:  Hippokratia       Date:  2018 Jul-Sep       Impact factor: 0.471

Review 2.  Combining cytotoxic and immune-mediated gene therapy to treat brain tumors.

Authors:  James F Curtin; Gwendalyn D King; Marianela Candolfi; Remy B Greeno; Kurt M Kroeger; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Top Med Chem       Date:  2005       Impact factor: 3.295

Review 3.  Gene therapy and targeted toxins for glioma.

Authors:  Maria G Castro; Marianela Candolfi; Kurt Kroeger; Gwendalyn D King; James F Curtin; Kader Yagiz; Yohei Mineharu; Hikmat Assi; Mia Wibowo; A K M Ghulam Muhammad; David Foulad; Mariana Puntel; Pedro R Lowenstein
Journal:  Curr Gene Ther       Date:  2011-06       Impact factor: 4.391

Review 4.  Gene therapy and targeted toxins for glioma.

Authors:  Gwendalyn D King; James F Curtin; Marianela Candolfi; Kurt Kroeger; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Gene Ther       Date:  2005-12       Impact factor: 4.391

5.  Anti-tumor effect of pEgr-IFNgamma gene-radiotherapy in B16 melanoma-bearing mice.

Authors:  Cong-Mei Wu; Xiu-Yi Li; Tian-Hua Huang
Journal:  World J Gastroenterol       Date:  2004-10-15       Impact factor: 5.742

6.  Gamma interferon transduced 9L gliosarcoma. Cytokine gene therapy and its relevance to cellular therapy with alloreactive cytotoxic T lymphocytes.

Authors:  David B Paul; Susana B Read; Nisha V Kulprathipanja; German G Gomez; B K Kleinschmidt-DeMasters; Patric M Schiltz; Carol A Kruse
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

7.  Retroviral transfer of the p16INK4a cDNA inhibits C6 glioma formation in Wistar rats.

Authors:  Bryan E Strauss; Ricardo BV Fontes; Claudimara FP Lotfi; Ana Skorupa; Ione Bartol; José Cipolla-Neto; Eugenia Costanzi-Strauss
Journal:  Cancer Cell Int       Date:  2002-04-04       Impact factor: 5.722

8.  Regulatory landscape and clinical implication of MBD3 in human malignant glioma.

Authors:  Yi Cui; Jian Li; Ling Weng; Sara E Wirbisky; Jennifer L Freeman; Jingping Liu; Qing Liu; Xianrui Yuan; Joseph Irudayaraj
Journal:  Oncotarget       Date:  2016-12-06

9.  Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy.

Authors:  Anhua Wu; Steve Wiesner; Jing Xiao; Katya Ericson; Wei Chen; Walter A Hall; Walter C Low; John R Ohlfest
Journal:  J Neurooncol       Date:  2006-11-01       Impact factor: 4.506

10.  TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM.

Authors:  Alice L Hung; Russell Maxwell; Debebe Theodros; Zineb Belcaid; Dimitrios Mathios; Andrew S Luksik; Eileen Kim; Adela Wu; Yuanxuan Xia; Tomas Garzon-Muvdi; Christopher Jackson; Xiaobu Ye; Betty Tyler; Mark Selby; Alan Korman; Bryan Barnhart; Su-Myeong Park; Je-In Youn; Tamrin Chowdhury; Chul-Kee Park; Henry Brem; Drew M Pardoll; Michael Lim
Journal:  Oncoimmunology       Date:  2018-05-24       Impact factor: 8.110

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.